Printer Friendly

Printed from http://www.researchandmarkets.com/reports/997661

UpdatesPlus Nicotinic Receptors - Current Research and Development - Issue 3, 2009

Description:
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.

Now we are seeing the field expand with peripheral nicotinic receptors gaining increasing attention in relation to further indications including various inflammatory conditions

Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.

And there's more...

Smoking cessation remains the one approved indication for the only commercially available selective nicotinic receptor ligand varenicline (Chantix/Champix). There is a considerable overlap between companies interested in nicotinic receptors and smoking cessation. UpdatesPlus therefore offers a detailed and up to date analysis of activity in the smoking cessation arena

Published monthly along with fully up to date pipelines, UpdatesPlus offers a key insight into strategy and development as well as new research advances. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
 
Contents:
a7 nicotinic receptors
- a7 receptor agonists as candidate early stage and potentially disease modifying treatments of schizophrenia - a7 receptor agonists have historically been investigated in schizophrenic patients already displaying psychoses. We believe that greater benefit may be gained by evaluating a7 receptor agonists in patients with very early stage, perhaps prodromic, disease. Find out how we believe nicotinic receptors can better meet their potential and generate greater revenue in schizophrenia
- Profile of SEN-12333 published – neuroprotection and procognitive activity demonstrated in Alzheimer’s disease models - SEN-12333 is unlikely to be developed clinically however we believe that its profile is encouraging. Find out all about SEN-12333 here.
- Full and up to date a7 receptor pipeline, all breaking R&D activity and patent activity

a4ß2 nicotinic receptors
- AstraZeneca continues to wait for ADHD data prior to deciding on future of AZD3480 – We provide an update on the development of AZD3480. Where is this candidate going? Has AstraZeneca started to evaluate AZD3480 as an adjunct to Seroquel in patients with resistant depression?
- Targacept to focus on mixed nicotinic receptor ligands for the treatment of pain - As well as partnering with AstraZeneca on the development of AZD-3480, Targacept was developing TC-6499 as candidate analgesics with GSK. Development has ceased. Why? What is the future of nicotinic ligands as analgesics?
- Vascular dementia emerges as a potential indication for a4ß2 receptor agonists - The development of nicotinic ligands has previously focussed on Alzheimer's disease however it is likely that the potential of a4ß2 receptor agonists may extend across the dementia spectrum. Read about the latest research to support this.
- Full and up to date a4ß2 receptor pipeline, all breaking R&D activity and patent activity

Other nicotinic receptors
- a5 receptor antagonists as candidate treatments of premenstrual dysphoric disorder (PMDD) - We believe that PMDD could be an excellent target for a5 receptor antagonists. The indication is unmet and could be worth upwards of $0.25 billion/year. If your company is involved in women's health, a5 receptors may be your next target.

Smoking cessation - Nicotine addiction
- Data argues against varenicline worsening depression - New data should be welcomed by Pfizer
- Varenicline reduces alcohol consumption in smokers - A new study has been published suggesting that varenicline may be of benefit to heavy drinkers as well as smokers. Curiously Pfizer has been relatively quiet with respect to this life cycle possibility
- Nabi’s NicVax represents an interesting licensing option for companies developing nicotinic smoking cessation products - Nabi had a rough ride at its most recent investor presentation. We believe that NicVax could represent an interesting licensing option especially for companies developing nicotinic receptor ligands
- Novartis finally opens phase 2 study of NIC002
- Full and up to date pipeline of smoking cessation therapeutics
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/997661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 18th 2014
3:02:54 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

UpdatesPlus Nicotinic Receptors - Current Research and Development - Issue 3, 2009

Web Address

http://www.researchandmarkets.com/reports/997661

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 1,263

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 18th 2014
3:02:54 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)